Diagnostic Efficacy of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Labeled Sodium Fluoride PET/CT in Prostate Cancer With Bone Metastasis.
10.3881/j.issn.1000-503X.15336
- Author:
An-Bo WANG
1
;
Li-Jia FENG
1
;
Ping-Ping NI
1
;
Li-Meng HE
2
;
Hong-Mei LI
3
;
Wei ZHANG
2
Author Information
1. Department of Nuclear Medicine,The First People's Hospital of Neijiang,Neijiang,Sichuan 641000,China.
2. Department of Nuclear Medicine,Sichuan Provincial People's Hospital,Sichuan Academy of Medical Sciences,Chengdu 610072,China.
3. Department of Nuclear Medicine,Affiliated Hospital of Southwest Medical University,Luzhou,Sichuan 646000,China.
- Publication Type:Journal Article
- Keywords:
PET/CT;
prostate cancer;
prostate-specific membrane antigen;
sodium fluoride
- From:
Acta Academiae Medicinae Sinicae
2023;45(4):634-639
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficiency of 68Ga-labeled prostate-specific membrane antigen (68Ga-PSMA-11) and 18F-labeled sodium fluoride (18F-NaF) PET/CT in the diagnosis of bone metastasis in the patients with prostate cancer.Methods The prostate cancer patients suspected of bone metastasis who underwent 68Ga-PSMA-11 PET/CT and 18F-NaF PET/CT from January 2018 to January 2021 were included in this study.The number of lesions,maximum standardized uptake value (SUVmax),and tumor-to-background (T/B) ratio were compared between the two methods.Results 18F-NaF PET/CT detected more metastases than 68Ga-PSMA-11 PET/CT (310 vs.264,P<0.001).The median SUVmax[23.2 (16.4,33.4) vs.4.1 (2.5,5.6)] and median T/B ratio[7.0 (4.9,9.9) vs.6.7 (3.7,9.6)] of 18F-NaF PET/CT were higher than those of 68Ga-PSMA-11 PET/CT (all P<0.001).With the number of lesions as the indicator,the sensitivity,specificity,accuracy,positive predictive value,and negative predictive value of 18F-NaF PET/CT were 100.0%,92.0%,92.0%,98.7%,and 100.0% respectively,and those of 68Ga-PSMA-11 PET/CT were 85.2%,94.0%,79.2%,98.9%,and 50.5%,respectively.Conclusion 18F-NaF PET/CT is superior to 68Ga-PSMA-11 PET/CT in the detection of bone metastases of prostate cancer.
